Soleno Therapeutics Management

Management Kriterienprüfungen 2/4

Soleno Therapeutics' CEO ist Anish Bhatnagar, ernannt in Feb 2014, hat eine Amtszeit von 8.5 Jahren. Die jährliche Gesamtvergütung beträgt $4.38M, bestehend aus 12.3% Gehalt und 87.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.2% der Aktien des Unternehmens, im Wert von €45.35K. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.6 Jahre bzw. 5.9 Jahre.

Wichtige Informationen

Anish Bhatnagar

Geschäftsführender

US$4.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	12.3%
Amtszeit als Geschäftsführer	8.5yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	5.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.9yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Anish Bhatnagar im Vergleich zu den Einnahmen von Soleno Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2022	n/a	n/a	-US$23m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$4m	US$538k	-US$31m
Sep 30 2021	n/a	n/a	-US$31m
Jun 30 2021	n/a	n/a	-US$31m
Mar 31 2021	n/a	n/a	-US$28m
Dec 31 2020	US$3m	US$504k	-US$25m
Sep 30 2020	n/a	n/a	-US$36m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$30m
Dec 31 2019	US$822k	US$470k	-US$31m
Sep 30 2019	n/a	n/a	-US$16m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$952k	US$460k	-US$12m
Sep 30 2018	n/a	n/a	-US$16m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$1m	US$446k	-US$12m
Sep 30 2017	n/a	n/a	-US$13m
Jun 30 2017	n/a	n/a	-US$11m
Mar 31 2017	n/a	n/a	-US$9m
Dec 31 2016	US$959k	US$460k	-US$10m
Sep 30 2016	n/a	n/a	-US$8m
Jun 30 2016	n/a	n/a	-US$10m
Mar 31 2016	n/a	n/a	-US$7m
Dec 31 2015	US$1m	US$435k	-US$10m

Vergütung im Vergleich zum Markt: AnishDie Gesamtvergütung ($USD4.38M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD385.52K).

Entschädigung vs. Einkommen: AnishDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Anish Bhatnagar (52 yo)

8.5yrs

Amtszeit

US$4,375,442

Vergütung

Dr. Anish Bhatnagar, M.D. has been Chief Executive Officer and Director of Soleno Therapeutics, Inc. since February 6, 2014 and serves as its President and Chief Operating Officer. Dr. Bhatnagar served as...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anish Bhatnagar	President	8.5yrs	US$4.38m	0.20% $ 45.4k
James MacKaness	Chief Financial Officer	1.8yrs	US$392.00k	0.055% $ 12.7k
Kristen Yen	Vice President of Clinical Operations	no data	US$821.67k	0.020% $ 4.7k
Patricia Hirano	Vice President of Regulatory Affairs	3.6yrs	US$920.83k	0.067% $ 15.3k
Anthony Wondka	Senior VP & GM	7.6yrs	US$270.00k	keine Daten
Neil Cowen	Senior Vice President of Drug Development	no data	keine Daten	keine Daten

5.6yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 6XC1 ist erfahren und erfahren (durchschnittliche Amtszeit: 5.6 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anish Bhatnagar	President	8.5yrs	US$4.38m	0.20% $ 45.4k
Ernest Mario	Independent Chairman	15yrs	US$176.36k	2.2% $ 505.9k
William Harris	Independent Director	8.2yrs	US$156.39k	0.11% $ 25.3k
Gwen Melincoff	Independent Director	3.3yrs	US$144.89k	0.0082% $ 1.9k
Thomas Casale	Member of Advisory Board	no data	keine Daten	keine Daten
Andrew Sinclair	Independent Director	3.7yrs	US$96.39k	0% $ 0
Robert Christensen	Member of Advisory Board	no data	keine Daten	keine Daten
Vinod Bhutani	Member of Advisory Board	no data	keine Daten	keine Daten
Birgitte Volck	Independent Director	3.2yrs	US$147.39k	0.087% $ 20.0k
Glenis Scadding	Member of Advisory Board	no data	keine Daten	keine Daten
David Stevenson	Member of Advisory Board	no data	keine Daten	keine Daten

5.9yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: 6XC1Die Vorstandsmitglieder gelten als erfahren (5.9 Jahre durchschnittliche Amtszeit).

Soleno Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Recent updates

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

New 90-day low: €1.14

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: €1.85

New 90-day high: €1.70

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

New 90-day low: €1.35

Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601)

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter